Bio-Techne Corporation's third-quarter fiscal 2026 results show mixed performance, with sales at $311.42 million and net income of $51.05 million, falling short of market expectations by 1.5%. While adjusted earnings per share decreased to $0.53, GAAP EPS rose to $0.32 from $0.14. Looking forward, the company aims for $1.5 billion in revenue by 2028, requiring consistent annual growth of 6.5% and a significant earnings increase. Analysts still favor Bio-Techne, noting a fair value that suggests a 33% upside from its current stock price.
“Bio-Techne · is ranked as · #85 analyst pick · moving up by 1 spot”
“Bio-Techne · has stock price movement year to date · lower · about 17.4%”
“Bio-Techne Corporation · has released · its third-quarter fiscal 2026 results”
“Bio-Techne Corporation · reported sales of · US$311.42 million”
“Bio-Techne Corporation · reported net income of · US$51.05 million”
“Bio-Techne Corporation · has higher basic and diluted earnings per share · from continuing operations · compared with a year earlier”
“Bio-Techne Corporation · increased profitability · indicating meaningful operating and margin improvements”
“Bio-Techne · projects · revenue of $1.5 billion by 2028”
“Bio-Techne · requires · 6.5% yearly revenue growth”
“Bio-Techne · requires · $176.7 million earnings increase from $73.4 million today”
“Bio-Techne · has a fair value of · $75.25 · a 33% upside to its current price”
“Bio-Techne · fell short of · market’s revenue expectations · 1.5%”